Company · Public · DNLI
Denali Therapeutics Inc.
Neurodegeneration company applying its Oligonucleotide Transport Vehicle to cross the blood-brain barrier; DNL628 (OTV:MAPT) is designed to reduce tau through MAPT targeting in Alzheimer's disease.
Listing
Public
Ticker
DNLI
Headquarters
—
Founded
—
Technology
Oligonucleotide Transport Vehicle (OTV), blood-brain barrier delivery
Category
Longevity thesis
Brain delivery is the limiting factor for oligonucleotide medicines in age-associated neurodegeneration; a transport vehicle that solves it applies across MAPT and beyond.
Programmes
- DNL628Phase 1b
Alzheimer's disease
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.